少弱精子症和正常生育男性精液中尿激酶及其受体含量的研究

目的:通过研究精子正常和异常男性精浆和精子中尿激酶及受体含量差异,以了解尿激酶及受体与男性生育力的关系。方法:采用双抗体夹心ELISA法测定22例正常生育男性和44例少弱精子症男性精浆和精子中尿激酶及受体的含量。结果:①正常男性精浆尿激酶平均含量为(4 803.69±602.78)mU/L,与少弱精子症组[(4 061.35±736.23)mU/L]相比,差异有显著性(P<0.01)。正常生育男性精子尿激酶平均含量为(30.29±3.16)mU/106个精子,与少弱精子症组[(20.51±4.2)mU/106个精子],差异有显著性(P<0.01)。②正常生育男性精子尿激酶受体平均含量为(12.97±3.11)mU/106个精子相比,与少弱精子症组[(6.09±1.45)mU/106个精子]相比,差异有显著性(P<0.01)。③精子和精浆中尿激酶含量和精子活率和活力呈显著正相关。结论:尿激酶和男性生育力相关,少弱精子症和正常生育男性精液中尿激酶及其受体含量存在差异。     

弱精子症、少弱精子症患者血清、精浆和精子锌含量分析

目的:检测弱精子症和少弱精子症患者血清、精浆和精子锌的含量,分析锌含量的变化与精子密度和精子运动之间的关系。方法:按照WHO《人类精液及精子-宫颈粘液相互作用实验室检验手册》第四版的标准进行精液质量分析,随机筛选出90例弱精子症、60例少弱精子症患者以及20例精液质量正常的生育者作为研究对象,利用原子吸收光谱法检测其血清、精浆、精子的锌含量并进行统计学分析。结果:3组间血清锌含量没有显著差异;弱精子症、少弱精子症患者精浆锌含量均显著低于正常生育者(P<0.05);少弱精子症患者精子锌含量显著高于弱精子症患者和正常生育者(P<0.01)。结论:弱精子症、少弱精子症患者精子的发生及运动功能下降可能与精浆锌含量的低下呈正相关;但过高的精子锌含量与精子的发生和运动功能的关系尚不十分明了,有待进一步研究。     

生育男性和异常精子症病人精浆一氧化氮水平的差异

目的 :通过研究精子正常和异常男性精浆中一氧化氮 (NO)含量及动态的差异 ,以了解NO与男性生育力的关系。　方法 :采用硝酸还原酶法 ,经Greiss试剂显色后 ,用分光光度法测定 174例生育男性和 2 17例异常精子症男性精浆中NO的含量。　结果 :① 174例精子生育男性精浆中均检测出NO ,平均含量为 (2 7.78± 5 .81) μmol/L,并随年龄增加而增高 ,40岁以后增高显著。 2 0～ 2 9岁组 [(2 6 .2 5± 5 .5 2 ) μmol/L]与 30～ 39岁组 [(2 8.11± 5 .87)μmol/L]相比 ,差异无显著性 (P >0 .0 5 ) ,但 40～ 49岁组 [(30 .17± 6 .14) μmol/L]与 2 0～ 2 9岁组相比 ,增高有统计学意义 (P <0 .0 5 )。② 9类精子异常症男性的精浆中NO含量均显著高于精子正常组。增高幅度以精子单项异常为最小 ,以精子的 3项异常为最高 ,2项精子异常的精浆中NO水平介于两者之间。　结论 :男性精浆中适度的NO可能具有调节精子发生的作用。     

少精子症患者血清、精浆中游离睾酮水平的测定及意义

目的 :通过测定少精子症患者血清、精浆中游离睾酮 (FT)水平 ,分析血清、精浆FT与少精子症的关系。　方法 :正常对照组 (n =4 4 )、少精子症组 (n =4 4 )男性于上午 8:0 0～ 10 :0 0留取血标本 ;正常对照组 (n =30 )、少精子症组 (n =37)同时留取精液。男性精液常规分析判断精子密度 ,放射免疫分析法测定血清、精浆中FT水平。　结果 :少精子症患者血清中FT浓度为 [(94 .88± 4 2 .0 4 )pmol/L],与正常对照组 [(97.5 0± 4 6 .96 )pmol/L]相比差异无显著性 (P >0 .0 5 ) ,但少精子症患者精浆中FT浓度 [(0 .5 2± 0 .4 4 ) pmol/L]显著低于正常对照组 [(2 .0 1±0 .32 )pmol/L],P <0 .0 1。　结论 :精浆中FT的测定较早反映睾丸的功能 ,有利于少精子症患者的早期诊断和治疗。     

精子顶体酶活性检测新方法与临床应用

以Na-苯甲酰-DL-精氨酸P-硝酰基苯胺(BAPNA)为底物,检测7.5×10~6去精浆精子顶体酶活性,孵育温度24℃,时间3小时,探讨和分析了最佳实验条件及注意事项.与此同时,检测了18例正常生育者精子(A组),16例精液常规基本正常者精子(B组),18例精液常规不正常者精子(C组).各组检测结果分别是29.7±14.3,19.4±10.9,6.9±7.7μIU/10~6精子(X±S),组间比较差异显著(P<0.05,P<0.001),提示顶体酶活性降低与生育力低下或不育相关.     

生育与不育男性精浆总抗氧化能力分析

目的:分析生育与不育男性精浆中总抗氧化能力(TAC)及其在男性生育中意义。方法:225例男性不育患者分为6组,分别为:梗阻性无精子症组(n=10),非梗阻性无精子症组(n=42),少精子症组(n=20),弱精子症组(n=78),少弱精子症组(n=57),以及正常精子症组(n=18)。28例正常生育男性作为对照(生育组)。分别采用计算机辅助精液分析(CASA)系统进行精液参数分析,采用比色法检测精浆TAC水平。结果:生育组男性精浆TAC为(19.82±6.33)U,梗阻性无精子症组(1.71±1.33)U,非梗阻性无精子症组(12.73±9.44)U,少精子症组(10.85±6.64)U,弱精子症组(13.88±8.24)U,少弱精子症组(11.20±7.02)U,正常精子症组(18.07±8.73)U;与生育组精浆TAC[(19.82±6.33)U]相比,在各不育症组中,除正常精子症组精浆TAC与生育组差异无显著性外,其余各组均显著低于生育组(P<0.01)。精浆TAC与精子密度(r=0.182,P<0.05)和a级精子(r=0.150,P<0.05)呈显著正相关。结论:精浆中TAC水平与男性不育密切相关,精浆中过低的TAC水平可能是引起男性不育的病因之一。     

复方玄驹胶囊联合维生素E对不育患者精子染色质损伤的影响

目的:初步探讨复方玄驹胶囊联合维生素E治疗方案对轻度少精子症和/或弱精子症患者精子染色质损伤的临床疗效。方法:50例精液异常的男性不育患者随机分为实验组(n=24)和对照组(n=26),分别予以复方玄驹胶囊+维生素E和单纯维生素E治疗3个月,运用计算机辅助精液分析系统(CASA)及精子染色质结构分析(SCSA)方法分析两组患者治疗前后精液常规参数和精子DNA损伤指数(DFI),比较治疗前后精液常规参数及精子DFI的变化。结果:实验组治疗后前向运动精子率为(21.55±8.68),对照组为(21.47±11.53),两组相比差异没有统计学意义(P>0.05)。在实验组中治疗前DFI为34.09±10.32,治疗后DFI为29.57±12.19,与治疗前相比显著下降(P<0.05)。结论:复方玄驹胶囊联合维生素E治疗可有效改善不育患者精液质量,对精子染色质损伤有一定的改善作用。     

几种离子及微量元素与人类精子运动相关性研究

本文应用浊度法和原子吸收光谱法,分别测定了精液中快速运动相精子的平均速度(VRM)和精浆中Na~+,K~+,Ca~(++),Mg~(++),Fe,Cu,Zn,Mn的含量。通过统计发现:1.正常有生育力者Na~+为2.5913±0.1399mg/mL,K~+1.2297±0.4189mg/mL,Mg~(++)0.1438±0.054mg/mL,Ca~(++)0.3089±0.1236mg/mL,Fe0.4087±0.1462μg/mL,Cu0.3383±0.1449μg/mL,Zn179.9±98μg/mL,Ma0.0446±0.043μg/mL。2.精子活动力差的不育患者,精浆中Mg~(++),Ca~(++),Cu及VRM均低于正常有生育力者。P<0.05。3.正常有生育力者VRM与精浆内Na~+含量有相关性。精子活动力差的不育患者VRM与精浆内Ca~(++),Cu含量有相关性。由此可见,VRM与精浆内多种成分有关,以与Na~+关系最为密切,其次是Ca~(++)和Cu。     

一氧化氮、一氧化氮合酶与伴精索静脉曲张不育患者精液参数的关系

目的:探讨一氧化氮(NO)、一氧化氮合酶(NOS)与伴精索静脉曲张(VC)不育患者精液参数之间的关系。方法:根据体格检查和彩色多普勒超声检查选择伴VC的不育患者(组1,n=53),其中临床型和亚临床型分别为21例和32例;同时选择非VC少弱精子症患者(组2,n=29)和正常生育者(组3,n=28)作对照组。采用硝酸还原法分别测定外周血和精浆中NO含量和NOS活性。用计算机辅助精液分析仪测定VC组患者精子密度、活动精子(a+b级精子)和快速前向运动精子百分率。结果:①组1外周血清NO含量和NOS活性与组2及组3相比差异无显著性(P>0.05),但精浆中NO含量和NOS活性组1明显高于其他两组,差异有显著性(P<0.01和P<0.05)。②组1中,随着曲张的精索静脉内径的增加,外周血清和精浆中NO含量和NOS活性均有所上升,但只有精浆中临床型和亚临床型之间相比差异有显著性(P<0.05)。③组1中,随着精子密度和精子活力的下降,外周血清和精浆中NO含量和NOS活性均有上升趋势,且精子密度≥20×106/ml和≤10×106/ml之间,精子活力≥50%和≤25%之间差异有显著性(P均<0.05)。结论:在VC诊断中精浆中NO含量和NOS活性测定较外周血清中更有意义。早期测定精浆NO含量和NOS活性对VC的诊断和治疗具有重要的临床价值。     

金匮肾气丸联合胰激肽原酶治疗弱精子症

目的:探讨金匮肾气丸联合胰激肽原酶治疗弱精子症的疗效及可能机制。方法:将75例弱精子症患者随机分成对照组(35例)和治疗组(40例),对照组口服Vit E胶囊,治疗组服用胰激肽原酶、金匮肾气丸;分别在治疗前和治疗3个月后检测精液量、精子浓度、前向运动精子比率、精浆超氧化物歧化酶,并观察配偶妊娠情况。结果:对照组治疗前、后的精液量为(3.15±1.13)m L、(3.68±1.24)m L,前向运动精子活动率为(26.54±4.52)%、(31.56±5.46)%,精浆SOD为(98.73±13.81)μmol/m L、(152.07±28.65)μmol/m L,组内差异具有统计学意义(P0.05);治疗组治疗前、后的精液量为(3.02±0.95)m L、(4.25±1.53)m L,精子浓度为(20.59±2.86)×106/m L、(28.97±4.25)×106/m L,前向运动精子活动率为(25.58±4.36)%、(48.76±9.38)%,精浆SOD为(102.95±12.74)μmol/m L、(203.43±37.86)μmol/m L,组内差异具有统计学意义(P0.05);且治疗组的改善程度优于对照组(P0.05)。结论:金匮肾气丸联合胰激肽原酶能显著改善弱精子症患者的精液活动率和精浆SOD,其作用机制可能是通过降低生精环境中的氧化应激损伤,改善精子活动率。     

强化胰岛素治疗对心肺转流术患者心血管功能的影响

目的 探讨强化胰岛素治疗对心肺转流术(CPB)患者血浆一氧化氮(NO)和内皮缩血管肽1(ET-1)表达的影响.方法 36例心脏瓣膜置换术患者随机分为常规治疗组(RT,n=18)和强化胰岛素治疗组(IT,n=18).RT组术中血糖变化不作处理,术后控制在13.9 mmol/L以内;IT组血糖术中控制在3.9～10.0 mmol/L,术后在3.9～6.1 mmol/L.分别于术前、CPB开始时及CPB结束后不同时间点测量两组患者的血浆NO和ET-1水平.结果 RT组血浆NO含量在CPB开始时即略有下降,CPB结束时达到最低(P＜0.05);此后回升,CPB结束后48 h时接近术前水平.RT组血浆ET-1含量在CPB开始时即开始升高,CPB结束时达高峰(P＜0.01);此后下降,至CPB结束后24 h时降至术前水平.IT组各时间点的血浆NO和ET-1含量与术前比较均无差异.结论 强化胰岛素治疗可减小CPB心脏手术中所致NO和ET-1的变化幅度,对心血管功能具有保护作用.     

高龄危重患者良性前列腺增生氩氦刀冷冻治疗研究(附21例报告)

目的:评价高龄危重患者BPH经皮冷冻的临床疗效。方法:使用ENDCARE冷冻手术系统,对72～91岁,同时伴有明显心肺功能障碍的21例BPH患者实施B超引导下的氩氦刀冷冻治疗,观察术后前列腺活检、前列腺超声图像、尿流率、血清PSA等变化。结果:术后前列腺组织出现变性、坏死,表现为完全消融现象;氩氦刀治疗前后平均尿流率分别为(3.8±2.1)、(17.0±5.8)ml/s(P<0.01);术前血清PSA(3.7±2.4)μg/L,术后1周(22.6±13.1)μg/L,与术前相比明显增高(P<0.01),术后4周(1.7±1.4)μg/L,与术前相比明显降低(P<0.05)。结论:经皮氩氦刀冷冻治疗BPH近期疗效满意,是高龄危重患者较好的治疗方法。     

聚精丸治疗少精子症的实验研究

目的:观察聚精丸对少精子症患者精子超微结构和生精细胞凋亡的影响,探讨聚精丸对精子生成的作用机制。方法:50例少精子症患者口服聚精丸5g/次,3次/d,3个月为1个疗程,连续服用1~4个疗程,分别于治疗前、治疗1、3、6、12个月后,通过透射电镜和流式细胞仪(FCM)观察精子超微结构和生精细胞的凋亡、生精细胞倍体比例的变化。结果:①精子超微结构治疗6个月后顶体基质密度有所增加,治疗12个月后顶体膜形态完整性有明显改善;核的病理改变和尾部异常改变不明显。②生精细胞凋亡治疗后细胞碎片和凋亡细胞减少,治疗3个月后与治疗前比较差异有显著性(P<0.05),治疗12个月后与治疗前比较差异有极显著性(P<0.01)。③生精细胞倍体比例经聚精丸治疗3个月后,单倍体成熟精子增多,与治疗前比较差异有极显著性(P<0.01);脱落的精母细胞减少,与治疗前比较差异有显著性(P<0.05)。结论:聚精丸可改善少精子症患者精子顶体基质密度和顶体膜结构形态的病理性改变,提高顶体膜和顶体酶的质量;降低生精细胞及精子凋亡速率,提高单倍体精子的百分率,降低二倍体细胞的百分率。     

Plasma adiponectin concentration before and after successful kidney transplantation

BACKGROUND: Adiponectin, a protein secreted exclusively by adipocytes, is presumed to be involved in the pathogenesis of atherosclerosis and insulin resistance. An elevated plasma adiponectin concentration was found in ESRD patients on hemodialysis (HD). However, the role of kidneys in adiponectin biodegradation/elimination is unknown. Therefore, we assessed plasma adiponectin concentrations in ESRD patients before and after successful kidney transplantation. METHODS: Among 44 hemodialyzed patients (29 men, 15 women; mean age 39 +/- 11 years; mean body mass index [BMI] 23.6 +/- 3.5 kg/m(2); mean duration of HD treatment before kidney transplantation 27 +/- 26 months), plasma adiponectin concentrations and insulin resistance indices (HOMA-R) were measured twice: immediately before kidney transplantation (Tx) and 1-2 days before patient discharge from the hospital with stable kidney transplant function (mean serum creatinine level 191 +/- 105 micromol/L). The control group consisted of 22 normotensive healthy subjects (12 men, 10 women). RESULTS: Among uremic patients, before Tx, plasma adiponectin concentrations were significantly higher than in healthy subjects (20.8 +/- 8.3 vs 8.7 +/- 4.8 microg/mL; P <.001) After successful Tx, plasma adiponectin concentrations decreased significantly (20.8 +/- 8.3 vs 15.7 +/- 7.0 microg/mL before and after Tx, respectively; P <.001). Simultaneously, after successful kidney transplantation, an increase in HOMA-R was observed (1.01 +/- 0.61 vs 1.43 +/- 0.83; P =.002). However, changes in adiponectinemia did not significantly correlate with serum creatinine or HOMA-R. CONCLUSION: The kidneys seem to play an important role in adiponectin biodegradation and/or elimination.     

Significance of serum neuron-specific enolase in patients with acute traumatic brain injury

OBJECTIVE: To study the association between serum neuron-specific enolase (NSE) and the extent of brain damage and the outcome after acute traumatic brain injury (TBI). METHODS: The release patterns of serum NSE in 78 patients after acute TBI were analyzed by using the enzyme linked immunosorbent assay. The levels of NSE were compared with Glasgow coma scale, the category of brain injury and the outcome after 6 months of injury. RESULTS: There were different NSE values in patients with minor (12.96 microg/L+/-2.39 microg/L), moderate (23.44 microg/L+/-5.33 microg/L) and severe brain injury (42.68 microg/L+/-4.57 microg/L). After severe TBI, the concentration of NSE in patients with epidural hematomas was 13.38 microg/L+/-4.01 microg/L, 24.03 microg/L+/-2.85 microg/L in brain contusion without surgical intervention group, 55.20 microg/L+/-6.35 microg/L in brain contusion with surgical intervention group, and 83.85 microg/L+/-15.82 microg/L in diffuse brain swelling group. There were close correlations between NSE values and Glasgow coma scale (r=-0.608, P<0.01) and the extent of brain injury (r=0.75, P<0.01). Patients with poor outcome had significantly higher initial and peak NSE values than those with good outcome (66.40 microg/L+/-9.46 microg/L, 94.24 microg/L+/-13.75 microg/L vs 32.16 microg/L+/-4.21 microg/L, 34.08 microg/L+/-4.40 microg/L, P<0.01, respectively). Initial NSE values were negatively related to the outcome (r=-0.501, P<0.01). Most patients with poor outcomes had persisting or secondary elevated NSE values. CONCLUSIONS: Serum NSE is one of the valuable neurobiochemical markers for assessment of the severity of brain injury and outcome prediction.     

One hundred sixteen cases of acute liver failure treated with MARS

The various definitions of acute liver failure do not accurately reflect the differences in clinical signs and prognosis. Liver support devices to improve the clinical condition before liver transplantation (LT) were used in 13 patients with primary nonfunction, 24 with fulminant hepatitis, 17 were affected by delayed nonfunction, and 56 of acute on chronic hepatic failure. The average age of these patients was 41.8 years. The average number of applications of molecular absorbing recirculating system (MARS) was about 6 (range: 1-24). The mean length of application was about 9 hours (range: 8-20). MARS treatment was carried out in HLF patients with continuous acute-on-chronic hepatic failure dialisate flow similar to continuous veno venus hemofiltration (CVVH), albumin flow < 20% of hematic flow, heparin 5/10 UI/kg. In acute on chronic hepatic failure (AoCHF) patients, 6- to 11-hour (average 8.5) treatments were performed for a minimum of three treatments. The majority of patients were treated in the intensive care unit (ICU). Laboratory results were also monitored and showed progressive modification: bilirubin (before treatment 22.37 +/- 11.6 mg/dL, after treatment 11.36 +/- 7.5 mg/dL) and ammonium (before treatment 238.2 +/- 19 microg/dL, after treatment 115.4 +/- 12 microg/dL) showed significant change (P < .01). Lactates (before treatment 3.48 +/- 1.3 mmol/L, after treatment 1.76 +/- 1.1 mmol/L) and creatinine (before treatment 2.36 +/- 0.18 mg/dL, after treatment 1.26 +/- 0.67 mg/dL) also showed significant changes (P < .02 and P < .04). Glasgow Coma Score (GCS) went from 8.6 +/- 1.4 to 11.9 +/- 3.9 (P < .05). The mean middle cerebral artery flow (V media) went from 46 cm/s/26-59) to 73 cm/s (52-106) representing decreased cerebral edema, a difference that was not significant. INR scores (before treatment 2.4 after treatment 1.8) also showed no significant change. The MARS can be applied with tolerability for long periods for patients with PDF and FH as a bridge to transplant. In patients with PDF, it is used for a waiting recovery of the transplanted organ. Therefore MARS can also limit the necessity to perform further transplants.     

Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis

To investigate the possible involvement of endogenous nitric oxide (NO) in acute hypotension during maintenance hemodialysis, we measured the plasma concentration of the nitrate anion NO3-, a stable metabolite of NO, in 19 patients undergoing hemodialysis. We analyzed heart rate variability to estimate the relationship between autonomic nervous activity and NO production, low-frequency/high-frequency components (L/H) as a parameter of cardiac sympathetic activity, and high-frequency power as a parameter of cardiac vagal activity. Six patients developed severe hypotension (a change in mean blood pressure during dialysis > or = 20 mm Hg), four patients developed mild hypotension (a change in mean blood pressure < or = 19 mm Hg and > or = 1 mm Hg), and nine patients did not develop hypotension. The plasma levels of NO3- before dialysis were markedly elevated in the severely hypotensive group compared with the patients who showed no hypotension (566+/-122 micromol/L v 133+/-38 micromol/L; P < 0.01), and this difference disappeared midhemodialysis and after hemodialysis. The plasma concentration of NO3- before dialysis was significantly associated with both the change in mean blood pressure during dialysis (r= -0.735; P = 0.003) and the mean blood pressure after dialysis (r = -0.675; P = 0.0015). The L/H ratio was inhibited before or after dialysis in the severely hypotensive group compared with the nonhypotensive group, and hypotension during dialysis was correlated with the inhibited L/H ratio before (r = 0.784; P = 0.001) or after (r = 0.822; P = 0.001) dialysis. Plasma NO3- concentrations were correlated with the L/H ratio before (r = -0.553; P = .014) or after (r = -0.546; P = 0.015) dialysis. These results suggest that inhibited sympathetic activity is one of the causes of acute hypotension during dialysis, and the enhanced production of NO is involved in this inhibition of the sympathetic activity in patients having a hypotensive episode during dialysis. The plasma concentration of NO3- before dialysis may be a predictor of the risk of hypotension during dialysis in patients with end-stage renal disease.     

左旋肉碱和乙酰左旋肉碱复合制剂对特发性弱精子症精子质量的影响

目的:观察左旋肉碱和乙酰左旋肉碱复合制剂对特发性弱精子症精子质量的影响。方法:采用自身对照实验设计。按WHO的标准诊断为特发性弱精子症的30例患者,经过中西医结合治疗无效后,服用左旋肉碱和乙酰左旋肉碱复合制剂,每次1袋,2次/d,疗程为3个月。应用本复合制剂前后按WHO标准进行精液分析各2次。结果:最终25例完成本观察。和治疗前比较,治疗后的精子存活率从(24.89±12.28)%提高为(49.45±17.40)%,精子活动力(a+b)级从(16.04±8.33)%提高为(24.64±7.09)%,一次射精的精子总数从(76.79±43.14)×106提高为(131.01±94.53)×106,有统计学显著差异(P<0.05)。结论:左旋肉碱和乙酰左旋肉碱对特发性弱精子症有辅助治疗效果,能提高患者的精液质量。     

G蛋白不同亚型在严重烫伤小鼠补体活化巨噬细胞分泌功能中的作用

目的观察严重烫伤后活化的补体对小鼠腹腔巨噬细胞(PM)分泌一氧化氮(NO)和肿瘤坏死因子(TNF)α的影响,探讨信号传递途径中不同G蛋白亚型的作用。方法血浆采集分组:补体血浆组,采用小鼠18%TBSAⅢ度烫伤模型;去补体血浆组,先在小鼠腹腔注射眼镜蛇毒素因子(CVF)去补体后再按上述标准烫伤。伤后6h分别收集两组小鼠全血制备血浆,用于培养正常小鼠的PM及经抑制型G蛋白(Gi)阻断剂百日咳毒素(PT)预处理的PM、经刺激型G蛋白(Gs)激活剂霍乱毒素(CT)预处理的PM,观察各组细胞培养上清液中NO及TNF-α含量的变化。结果补体血浆组培养上清液中的NO和TNF-α含量分别为(80±12)μmol/L和(46±6)%,明显高于去补体血浆组的(34±5)μmol/L和(26±5)%(P<0.01).PT预处理后补体血浆组PM产生的NO明显下降[(45±10)μmol/L,P<0.01],而TNF-α活性[(58±10)%]增加(P<0.05),CT预处理后补体血浆组PM产生的NO增加[(105±18)μmol/L,P<0.05],TNF-α的活性[(27±6)%]降低(P<0.01).结论严重烫伤后活化补体引起PM分泌NO和TNF-α增多这一现象,至少部分是通过G蛋白途径实现的。其中对PM生成NO的调控主要是通过Gi蛋白途径发挥作用,对PM分泌TNF-α的调控则以Gs蛋白信号通路为主。     

The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure

In the hemodialysis patient, hemostasis changes may occur. The contribution of fibrinolysis in pathogenesis of these disorders is unclear. The aim of the study was to estimate intrinsic fibrinolysis pathway in patients treated with hemodialysis (HD) because of chronic renal failure caused by chronic glomerulonephritis. The study was performed with 43 patients; the control group consisted of 51 healthy volunteers chosen by sex and age. The following parameters were determined: concentration of the urokinase plasminogen activator antigen (uPA:Ag), plasmin--antiplasmin complexes (PAP), fibrin and fibrinogen degradation products (FDP), activity of prekallikrein (PK) and C1-inhibitor (C1-INH) and also euglobulin clot lysis time (ELT). The above parameters were assessed in the patients before and after HD and were compared with the control group. In the HD patients, in comparison with the control group, prolonged statistically ELT [153 (125;215) vs. 105 (75;142) min.; p<0.001], with increase of PAP (508.6 +/- 274.7 vs. 184.7 +/- 69.4 microg/L; p<0.001) and FDP concentrations [5 (5;15) vs. 2.5 (0;0.3) microg/mL; p<0.05] before the procedure were determined. It suggests increased plasmin production and fibrin digestion despite determination of decreased general fibrinolytic activity. The C1-INH activity before HD was also significantly increased as compared with the control group [157 (136;171) vs. 107 (100;124)%; p<0.001], and its significant decreased after the HD is 157.7 +/- 23.9 vs. 122.3 +/- 20.3%; p<0.001, as it seems to be a nondirect proof of intrinsic pathway contribution in fibrinolysis activation in the HD patients. The remaining examined parameters did not change significantly after the dialysis procedure.